DANIELLE AYR TAVARES DE ALMEIDA

Dr. DANIELLE AYR TAVARES DE ALMEIDA

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LPLuciane Barbosa Pessoa
Luciane Barbosa Pessoa
LALucas Polizzeli Azevedo
Lucas Polizzeli Azevedo
AMAline Aparecida Macedo Marques
Aline Aparecida Macedo Marques
JPJuliane Barbosa Pessoa
Juliane Barbosa Pessoa
LPLuana Ale Bertoncello Pael
Luana Ale Bertoncello Pael
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior

21 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMaria Medina De Azevedo
Maria Medina De Azevedo
Francislaine Aparecida dos Reis LíveroFrancislaine Aparecida dos Reis Lívero
Francislaine Aparecida dos Reis Lívero
STSílvia Beatriz Bürger Tinelli
Sílvia Beatriz Bürger Tinelli
JSJacenir Vieira da Silva
Jacenir Vieira da Silva
DADANIELLE AYR TAVARES DE ALMEIDA
DANIELLE AYR TAVARES DE ALMEIDA
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior
Attalea phalerata Martius ex Spreng is a palm tree that is widely distributed in the Central-West region of Brazil. In this study, we investigated whether the oil-loaded nanocapsules of A. phalerata (APON) have acute and long-lasting antihypertensive effects in male spontaneously hypertensive rats (SHR), as well as explored the underlying molecular mechanisms. APON was prepared using the interfacial polymer deposition method. The particle size, polydispersity index, and zeta potential were investigated using dynamic and electrophoretic light scattering. The antihypertensive effects of APON (administered at doses of 1, 3, and 10 mg/kg) were evaluated after acute intraduodenal administration and after 7 days of oral treatment. To investigate the molecular pathways involved, we used pharmacological antagonists and inhibitors that target prostaglandin/cyclic adenosine monophosphate, nitric oxide/cyclic guanosine monophosphate, and potassium channels. Both acute and prolonged administration of APON (at doses of 3 and 10 mg/kg) resulted in a significant reduction in systolic, diastolic, and mean arterial pressure. Prior treatment with a non-selective nitric oxide synthase inhibitor (Nω-nitro-L-arginine methyl ester), guanylyl cyclase inhibitor (methylene blue), or non-selective calcium-sensitive K+ channel blocker (tetraethylammonium) abolished the antihypertensive effects of APON. Our study showed that A. phalerata oil-loaded nanocapsules have a significant antihypertensive effect in SHR after both short-term and long-term (7-day) use. This effect seems to rely on the vascular endothelium function and involves the NO-cGMP-K+ channel pathway. This research suggests a new direction for future studies to definitively prove the therapeutic benefits of APON in treating cardiovascular disease.

16 December 2025 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
LKLislaine Maria Klider
Lislaine Maria Klider
AMAline Aparecida Macedo Marques
Aline Aparecida Macedo Marques
KMKaryne Moreno
Karyne Moreno
GSGabriela Pereira da Silva
Gabriela Pereira da Silva
KSKelly Cristina Barboza dos Santos
Kelly Cristina Barboza dos Santos
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior